Alkermes’ Lumryz Hits Phase 3 Mark in Another Sleep Disorder, Fueling Momentum from $2.4B Avadel Acquisition
Alkermes has achieved a significant milestone with its sodium oxybate drug Lumryz, successfully meeting all primary and key secondary endpoints in a phase 3 study targeting a rare sleep disorder. This clinical success follows the company’s strategic $2.37 billion acquisition of Avadel, which has now begun to bear fruit less than a year after the…
